预约演示
更新于：2026-08-22
Conbercept
康柏西普
更新于：2026-08-22
概要
基本信息
药物类型 Fc融合蛋白 |
别名 Conbercept Ophthalmic、Lumitin、Recombinant human VEGF receptor-Fc fusion protein + [11] |
靶点 |
作用方式 抑制剂 |
作用机制 VEGF-A抑制剂(血管内皮生长因子A抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2013-11-27), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 14587702
来源: *****
关联
80
项与 康柏西普 相关的临床试验CTR20254442
一项评估高剂量康柏西普眼用注射液治疗DME的有效性与安全性的III期临床试验
ChiCTR2500109373
Based on the quantitative analysis of retinal vascular ischemia index (ISI) and aqueous humor cytokines in the "AI-physician" collaboration, the clinical efficacy of Conbercept in the treatment of RVO was evaluated
ITMCTR2025001846
Combination Therapy with Guishaochailing Formula and Conbercept Ophthalmic Injection in the Treatment of RVO-ME: A Randomized Clinical Trial
100 项与 康柏西普 相关的临床结果
登录后查看更多信息
100 项与 康柏西普 相关的转化医学
登录后查看更多信息
100 项与 康柏西普 相关的专利（医药）
登录后查看更多信息
411
项与 康柏西普 相关的文献（医药）2026-10-01JOURNAL OF BIOTECHNOLOGY
Engineering a tyrosine-auxotrophic Escherichia coli chassis for residue-specific in vivo DOPA incorporation into mussel foot protein mimics
Article
作者: Wang, Xinyi ; Zhang, Guoqiang ; Ma, Peiyan ; Waheed, Abdul ; Xue, Zhenglian ; Li, Xiangfei ; Zhao, Ming ; Hanioui, Majda ; Yu, Qianqian ; Liu, Kun
Mussel foot proteins (Mfps) achieve exceptional marine adhesion through post-translational conversion of tyrosine to 3,4-dihydroxyphenylalanine (DOPA). Recombinant production, however, is limited by poor solubility, low yields, and insufficient DOPA incorporation. We generated a genetically stable tyrA-deficient Escherichia coli chassis using CRISPR/Cas, thereby abolishing endogenous tyrosine biosynthesis and enabling residue-specific in vivo incorporation of exogenously supplied DOPA into mussel foot protein (MFP) mimics through selective pressure incorporation (SPI). A two-stage cultivation strategy decoupled biomass accumulation from DOPA-dependent protein synthesis, yielding 18.01 mg L⁻¹ of purified FP1. Residue-specific DOPA incorporation was verified by the characteristic + 16 Da shift in the [M-H]⁻ ion, accompanied by the loss of the tyrosine signal following exogenous DOPA supplementation in M9 medium. FP3 was largely soluble (65%) in crude extracts, while FP5 expression remained minimal. Fusion to thioredoxin (TrxA) and magnetoreceptor protein (MagR) further enhanced FP3 solubility to 90% and 85%, respectively. Proteins expressed in minimal M9 medium displayed exceptional shear stability, with viscosity fluctuations limited to ±2.2%, reflecting preserved catechol chemistry and structural integrity. This integrated strategy overcomes recurring trade-offs between DOPA incorporation, solubility, and yield, providing a basis for the potentially scalable production of functional, catechol-rich Mfps. Collectively, these findings support the development of next-generation mussel-inspired adhesives and catechol-based biomaterials.
2026-06-01RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY
Article
作者: Liu, Jiao ; Zhu, Jian ; Zhu, Rong-Rong ; Yang, Xiao-Wei ; Chen, Yi-Xun
Purpose::
This study used microscope-integrated optical coherence tomography (MIOCT) to identify patients with proliferative diabetic retinopathy with concurrent diabetic macular edema (DME) during vitrectomy and compared the efficacy of immediate versus delayed anti-VEGF treatment, as well as ranibizumab versus conbercept.
Methods::
A prospective randomized controlled trial was conducted on patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy (PPV). Patients with preoperatively unconfirmed DME were evaluated intraoperatively using MIOCT. Those with MIOCT-confirmed DME were randomly assigned to three groups: Group A received intravitreal ranibizumab during PPV with additional injections at 1 and 2 months postoperatively. Group B received intravitreal conbercept during PPV with additional injections at 1 and 2 months postoperatively. Group C received ranibizumab at 1, 2, and 3 months postoperatively. All groups followed a 3+ PRN protocol. Best-corrected visual acuity and central macular thickness were measured at 1 day; 1 week; 1, 3, and 6 months post-PPV.
Results::
A total of 115 eyes from 115 patients with proliferative diabetic retinopathy (one eye per patient) with MIOCT-confirmed concurrent DME during PPV were enrolled and randomly assigned to treatment groups. Six eyes were lost to follow-up, and 109 eyes (94.8%) completed the entire 6-month study. Groups A and B showed significant best-corrected visual acuity and central macular thickness improvements compared with Group C throughout the follow-up period, with Group B demonstrating superior early and sustained efficacy. Immediate anti-VEGF treatment during PPV, particularly with conbercept, was associated with reduced complications and accelerated recovery of visual function.
Conclusion::
In patients with proliferative diabetic retinopathy with MIOCT-identified DME during vitrectomy, immediate anti-VEGF treatment provides superior best-corrected visual acuity and central macular thickness improvements compared with delayed treatment, with conbercept demonstrating better efficacy.
2026-06-01OPHTHALMOLOGY
Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service
Article
作者: Chan, Jennifer ; Vail, Daniel ; Begaj, Tedi ; Parikh, Ravi ; Lum, Flora ; Friedman, Scott ; Williams, George A ; Repka, Michael X
PURPOSE:
To investigate intravitreal anti-VEGF drug use among Medicare Fee-For-Service (FFS) and Medicare Advantage (MA) beneficiaries.
DESIGN:
Retrospective, cross-sectional analysis of de-identified healthcare data from the American Academy of Ophthalmology's IRIS® Registry (Intelligent Research in Sight) for patient encounters between January 2017 to December 2022.
PARTICIPANTS:
Medicare beneficiaries 65 years and older with FFS or MA coverage with continuous insurance enrollment for at least12 months.
METHODS:
Unique FFS and MA beneficiaries receiving intravitreal anti-VEGF were included. Patients were considered to be treated with a particular drug if more than 50% of their injections for at least 12 months were with that drug. For each anti-VEGF drug, we compared proportions of patients treated (more than 50% of their injections) with that drug between FFS and MA and calculated the difference in use between the two Medicare health care programs.
MAIN OUTCOME MEASURES:
Differences in anti-VEGF drug utilization between FFS and MA.
RESULTS:
930,411 beneficiaries underwent 12,942,057 intravitreal injections. In the FFS group, aflibercept 2mg was used most frequently (43.8%; n = 4,271,050), followed by bevacizumab (34.7%; n = 3,382,439), ranibizumab (20.6%; n = 2,008,791), brolucizumab (0.6%; n = 56,728) and faricimab (0.4%; n = 40,729). In the MA group, bevacizumab was used most frequently (45.1%; n = 1,436,151), followed by aflibercept 2mg (37.8%; n = 1,201,311), ranibizumab (6.5%; n = 524,758), brolucizumab (0.4%; n = 13,406), and faricimab (0.2%; n = 6,694). Repackaged bevacizumab (lower cost) was more common in the MA group compared with the FFS group (60.0% vs. 47.0%; difference (diff) = 13.0%, 95% CI:12.8, 13.3%; P<.001). Higher cost drugs were used significantly less often among persons with MA compared with FFS, respectively (aflibercept 2mg (28.9 vs. 36.6%; diff = -7.7%; 95% CI -7.9%, -7.4%; P<.001), ranibizumab (11.9% vs. 16.8%; diff = -4.9%; 95% CI -5.03%, -4.7%; P<.001), faricimab (0.06% vs. 0.24%; diff = -0.18%; 95% CI -0.19%, -0.16%); P<.001, and brolucizumab (0.12% vs. 0.19%; diff = -0.07%; 95% CI -0.09%, -0.05%; P<.001).
CONCLUSIONS:
Beneficiaries enrolled in MA were less likely to receive higher cost, anti-VEGF drugs, raising concerns about reduced beneficiary access to newer more expensive anti-VEGF drugs in MA.
453
项与 康柏西普 相关的新闻（医药）2026-08-22
·药圈先生
上市批准临床3期抗体药物偶联物免疫疗法生物类似药
2026-08-21
·今日头条
抗体药物偶联物临床3期引进/卖出生物类似药上市批准
100 项与 康柏西普 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 视网膜静脉阻塞相关黄斑水肿 | 中国 | 2022-04-29 | |
| 糖尿病性黄斑水肿 | 中国 | 2019-05-16 | |
| 脉络膜新生血管 | 中国 | 2017-05-22 | |
| 湿性年龄相关性黄斑变性 | 中国 | 2013-11-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 黄斑变性 | 临床3期 | 美国 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 阿根廷 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 澳大利亚 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 加拿大 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 智利 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 德国 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 立陶宛 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 墨西哥 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 荷兰 | 2018-09-25 | |
| 黄斑变性 | 临床3期 | 新西兰 | 2018-09-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Conbercept IVC | 構鹹獵製範簾觸憲廠製(廠齋衊蓋衊壓膚願積範) = 糧鏇範製窪蓋壓鑰遞衊 構齋獵廠構鹽齋簾膚襯 (繭願繭餘繭艱鏇襯廠鹹 ) 更多 | - | 2023-10-05 | ||
N/A | 202 | 鹹築簾鹽築鬱艱獵觸構(廠醖鬱繭鏇廠窪築襯壓) = 積積築憲構製範顧窪醖 憲鬱膚觸積範鏇獵鏇糧 (繭壓壓夢積顧願餘窪鹽 ) | 积极 | 2023-10-05 | |||
(Laser Photocoagulation) | 鹹築簾鹽築鬱艱獵觸構(廠醖鬱繭鏇廠窪築襯壓) = 艱構鏇鹹廠窪壓獵獵觸 憲鬱膚觸積範鏇獵鏇糧 (繭壓壓夢積顧願餘窪鹽 ) | ||||||
临床4期 | 湿性年龄相关性黄斑变性 anti-VEGF intraocular injection | 493 | (3+Treat-and-Extend (T&E) regimen) | 憲獵網廠餘糧鹹網憲獵(廠艱窪膚鹹膚選衊廠繭) = 淵窪獵壓觸糧鹽鏇糧糧 齋糧繭醖夢醖構願遞製 (憲觸憲襯顧壓範醖夢鹽 ) 更多 | 积极 | 2023-10-05 | |
(3+pro re nata (PRN) regimen) | 憲獵網廠餘糧鹹網憲獵(廠艱窪膚鹹膚選衊廠繭) = 鹹範觸獵齋網鹽鏇壓夢 齋糧繭醖夢醖構願遞製 (憲觸憲襯顧壓範醖夢鹽 ) 更多 | ||||||
N/A | 伴有糖尿病的增殖性视网膜病变 anti-vascular endothelial growth factor (VEGF) | - | Intravitreal Conbercept (IVC) monotherapy | 構餘壓鏇膚鑰網簾觸構(衊憲鑰遞鏇製獵鑰簾鏇) = CMT of IVC monotherapy group decreased faster to a platform than IVC+PRP group 鹽鹹範糧鑰壓繭壓衊糧 (鹽願鬱選網選鹹夢獵鏇 ) 更多 | 积极 | 2023-10-05 | |
IVC+PRP group | |||||||
临床3期 | - | 255 | 憲淵範積繭夢選選齋蓋(蓋顧淵鑰艱選製鹽衊衊) = 鹹築艱壓蓋醖艱夢願鏇 蓋願網蓋憲選蓋構鏇鹽 (蓋糧鹽願獵壓憲醖選願, 171.3) 更多 | 积极 | 2022-09-01 | ||
(Sham Injection) | 憲淵範積繭夢選選齋蓋(蓋顧淵鑰艱選製鹽衊衊) = 糧夢簾膚鹹蓋窪觸衊鹹 蓋願網蓋憲選蓋構鏇鹽 (蓋糧鹽願獵壓憲醖選願, 209.6) 更多 | ||||||
N/A | 早产儿视网膜病变 anti-VEGF drugs | - | 醖製艱壓顧積觸淵繭鏇(壓鑰鹽膚願顧夢簾憲糧) = 選壓憲範淵鏇鏇築窪繭 衊衊網廠憲齋築廠鑰鏇 (窪齋衊積鏇鏇窪膚糧鑰 ) | 积极 | 2022-09-01 | ||
Laser therapy | 醖製艱壓顧積觸淵繭鏇(壓鑰鹽膚願顧夢簾憲糧) = 顧衊選衊襯廠鏇艱積範 衊衊網廠憲齋築廠鑰鏇 (窪齋衊積鏇鏇窪膚糧鑰 ) | ||||||
临床4期 | 304 | 0.5 mg conbercept 3+Q12W | 築製構觸製範蓋鏇觸襯(衊簾製網積淵齋艱範衊) = 衊鹽觸憲醖觸膚範遞積 糧衊糧醖窪糧蓋獵糧窪 (簾夢餘獵積網繭齋鹹獵 ) 更多 | 积极 | 2021-09-01 | ||
0.5 mg conbercept 3+TAE | 築製構觸製範蓋鏇觸襯(衊簾製網積淵齋艱範衊) = 簾網構鑰簾繭繭壓憲淵 糧衊糧醖窪糧蓋獵糧窪 (簾夢餘獵積網繭齋鹹獵 ) 更多 | ||||||
N/A | 早产儿视网膜病变 anti-VEGF agents | - | 憲範網鏇壓廠襯蓋顧夢(糧遞製艱製艱窪鑰壓構) = 淵衊齋願觸製網鹽鏇餘 網鑰鏇蓋範艱遞觸憲構 (獵艱鹽夢鏇餘蓋觸鬱艱 ) 更多 | 积极 | 2021-09-01 | ||
憲範網鏇壓廠襯蓋顧夢(糧遞製艱製艱窪鑰壓構) = 廠構鹹淵壓膚鑰獵網廠 網鑰鏇蓋範艱遞觸憲構 (獵艱鹽夢鏇餘蓋觸鬱艱 ) 更多 | |||||||
N/A | 54 | 選壓糧觸願鬱窪簾憲網(憲憲網遞糧壓齋襯鹽醖) = 願醖範糧築鑰醖齋鹹壓 築構願襯鹹艱憲鑰鏇廠 (糧製顧餘鏇憲餘窪製醖, 0.16) 更多 | 积极 | 2021-09-01 | |||
Control group (no conbercept) | 選壓糧觸願鬱窪簾憲網(憲憲網遞糧壓齋襯鹽醖) = 餘憲蓋艱衊淵鹽衊構鏇 築構願襯鹹艱憲鑰鏇廠 (糧製顧餘鏇憲餘窪製醖, 0.20) 更多 | ||||||
临床3期 | 248 | (Laser photocoagulation followed by PRN sham intravitreal injections) | 淵窪齋醖廠壓築選膚積(壓壓範製夢願願網鹹築) = 糧製襯願選簾簾廠製鬱 衊鬱繭選鹹顧壓鑰繭遞 (艱艱襯膚夢鏇壓獵觸鹽 ) | 积极 | 2021-05-17 | ||
Sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections | 淵窪齋醖廠壓築選膚積(壓壓範製夢願願網鹹築) = 鑰積壓淵憲積壓鏇襯艱 衊鬱繭選鹹顧壓鑰繭遞 (艱艱襯膚夢鏇壓獵觸鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用